Avery Dennison stresses supply chain security at Pharmapack Europe
Press Release | Avery Dennison
JANUARY 31, 2018
Oegstgeest, The Netherlands: – Worldwide labeling leader Avery Dennison is headed for Pharmapack Europe 2018 in Paris to showcase a range of sophisticated new products designed to address different aspects of pharma supply chain security.
The Avery Dennison stand at Booth M26 at the Porte de Versailles exhibition center will feature a wide range of products, headlined by three landmark solutions, all recently introduced.
- The new Tamper-evident Seal portfolio comprises a range of materials all secured by the S799P adhesive that offers superior performance on most varnished cardboard, making it harder to interfere with cartons and enabling easier compliance with the imminent EU Medicine Directive. This is designed to prevent “falsified medicines” entering the legal supply chain that applies to all prescription and some OTC medicinal products, requiring outer packaging to reveal any tampering, from February 2019 onwards.
- TT Sensor Plus™ 2 is a ‘smart label’ that records time and temperature data on temperature-sensitive products, such as pharmaceuticals, biotech medicines and vaccines. It also provides a complete solution with multiple services such as a cloud environment, computer software, a mobile APP, and an application programming interface (API). Data are stored in a near field communication (NFC) chip and can be uploaded to the cloud via a smartphone or a computer at anytime, anywhere throughout the supply chain. When affixed to a product or container, TT Sensor Plus™ 2 can be programmed by the user to record the temperature history of goods at defined intervals during shipment.
- Avery Dennison S717P emulsion acrylic adhesive technology provides an effective solution to reduce ‘label lift’ on challenging pharma applications, such as plastic/treated glass syringes, and vials, where low energy surfaces and/or small diameters place enormous demands on the label. S717P also offers a rapid recertification process. The ‘P’ suffix indicates it is part of Avery Dennison’s dedicated pharma range, maintained as a stable product with formal change management control with 12 months notification times in place where changes have to be made. Certificates are in place for migration, toxicology and food applications, reducing re-qualification costs by around 20-30% compared with a start-from-scratch approval process with standard syringe labeling, thus speeding up re-certification.
Falsified Medicines Directive priority
“With the EU’s new Falsified Medicines Directive 2011/62 EU due to come into force a year from now, tamper-evidence on packaging and supply chain security have become front-of-mind issues for Pharma manufacturers and end users,” commented Gabriela Gregor, Avery Dennison Product Manager Pharmaceuticals Europe.
“At Pharmapack, we will be showing solutions to the more complex challenges of providing secure labeling and sealing on challenging shapes and surfaces, along with greater control over cool-chain logistics,” said Ms. Gregor.
“Visitors to our stand will be able to get hands-on with our new labeling ranges as well as see temperature and monitoring in real time via TT Sensor Plus™ 2 linked to mobile platforms,” she added.
About Avery Dennison
Avery Dennison (NYSE: AVY) is a global leader in pressure-sensitive and functional materials and labelling solutions for the retail apparel industry. The company’s applications and technologies are an integral part of products used in every major industry. With operations in more than 50 countries and more than 25,000 employees worldwide, Avery Dennison serves customers in the consumer packaging, graphical display, logistics, apparel, industrial and healthcare industries. Headquartered in Glendale, California, the company reported sales of $6.1 billion in 2016. Learn more at: www.averydennison.com.
About Pharmapack 2018
Pharmapack Europe is the leading European conference and exhibition in the field of pharmaceutical packaging and drug delivery systems, showcasing major trends in the sector, both in terms of emerging markets and technological innovation.
The 17th Pharmapack Europe conference is a two-day event opening February 7, 2018, at Paris Expo, Porte de Versailles. Organizers UBM Live changed the venue in 2014, to reflect increased attendance, currently totaling some 5,300 visitors and more than 400 exhibitors from around 70 countries.
Pharmapack Europe 2018 will again combine an industry exhibition with a full conference and technical symposium program.
The Pharmapack Awards, presented during the afternoon of Day 0ne, will reward outstanding achievements in two categories: innovative Health Products and Exhibitor Innovation, recognizing outstanding products or displays from the exhibition floor.
Further information is available at: www.pharmapackeurope.com.
Rob Verbruggen, Director Communications, Avery Dennison LPM
Tel: +31 650831340